Glenmark gets favourable interim award against Napo Pharma

Glenmark Pharmaceuticals said it has received a favourable interim award in a dispute against Napo Pharmaceuticals regarding commercialisation of anti-diarrheal drug, Crofelemer, from International Centre for Dispute Resolution (ICDR).

"The ICDR ruled that Glenmark's exclusive rights to commercialise and distribute Crofelemer include the exclusive right to distribute Crofelemer through relief agencies into the 140 countries that comprise the Glenmark territory," Glenmark Pharmaceuticals said in a filing to the BSE.

Glenmark Pharmaceuticals has an exclusive licence from Napo Pharmaceuticals Inc to distribute and commercialise Crofelemer in 140 emerging countries. Reuters

The ICDR found that US-based Napo "breached the collaboration agreement by disclosing confidential information concerning the manufacture of Crofelemer to Aptuit Laurus." Aptuit Laurus is a US-based drug development company.

ICDR also enjoined Napo from disclosing such confidential information to third parties and from purchasing or obtaining Crofelemer from Aptuit, it added. The ruling today is an interim award addressing the issues presently before the ICDR. Certain other issues between the parties have been deferred to a second phase, Glenmark said.

Commenting on the development Glenmark Pharmaceuticals Chairman & MD Glenn Saldanha said: "We are delighted that the arbitrators have reaffirmed Glenmark's rights to commercialise Crofelemer through relief agencies." "We also are pleased that the arbitrators have prevented Napo from sharing confidential information concerning the manufacture of Crofelemer with our competitors and other third

parties, he added.

Glenmark Pharmaceuticals has an exclusive licence from Napo Pharmaceuticals Inc to distribute and commercialise Crofelemer in 140 emerging countries (rest of world territories) including India for indications related to HIV, use in acute adult and pediatric diarrhea, the company said.

Shares of Glenmark Pharmaceuticals were today trading at Rs 413.65 in the afternoon trade on BSE, up 2.09 percent from its previous close.

PTI


Updated Date: Dec 20, 2014 11:27 AM

Also Watch

IPL 2018: Royal Challengers Bangalore eye revival against Chennai Super Kings as 'Cauvery Derby' comes back to life
  • Thursday, April 26, 2018 In the Kanjarbhat community, a campaign against 'virginity tests' is slowly gaining ground
  • Tuesday, April 24, 2018 It's A Wrap: Beyond the Clouds stars Ishaan Khatter, Malavika Mohanan in conversation with Parul Sharma
  • Monday, April 9, 2018 48 hours with Huawei P20 Pro: Triple camera offering is set to redefine smartphone imaging
  • Monday, April 16, 2018 Rajyavardhan Singh Rathore interview: Sports can't be anyone's fiefdom, we need an ecosystem to nurture raw talent

Also See